{"id":"aclidinium-bromide-200-g","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Urinary retention"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aclidinium is a quaternary ammonium anticholinergic compound that selectively antagonizes muscarinic M3 receptors on airway smooth muscle and mucus glands. By blocking acetylcholine-mediated bronchoconstriction, it produces sustained bronchodilation and reduces mucus secretion. The drug is formulated as a dry powder inhaler for maintenance treatment of chronic obstructive pulmonary disease (COPD).","oneSentence":"Aclidinium bromide is a long-acting muscarinic antagonist that blocks M3 receptors in airway smooth muscle to prevent bronchoconstriction and improve airflow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:59:02.865Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) maintenance treatment"}]},"trialDetails":[{"nctId":"NCT00706914","phase":"PHASE2","title":"Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2008-06-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":156},{"nctId":"NCT01044459","phase":"PHASE3","title":"Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":605},{"nctId":"NCT01045161","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":544},{"nctId":"NCT00435760","phase":"PHASE3","title":"Clinical Trial to Assess Rate of Onset of Bronchodilator Action in Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-02","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":115}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Aclidinium Bromide 200 µg","genericName":"Aclidinium Bromide 200 µg","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aclidinium bromide is a long-acting muscarinic antagonist that blocks M3 receptors in airway smooth muscle to prevent bronchoconstriction and improve airflow. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}